Vanda Pharmaceuticals Inc.
$3.45-$0.22 (-6.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $375.8M
- Revenue
- $216.1M
- Net margin
- -102.0%
- ROCE
- -46.2%
Price chart
Technical chartScreen technicals →-28.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -17.3%
- 3M
- -35.9%
- 6M
- -44.2%
- 1Y
- -28.7%
- 5Y
- -79.7%
52-week range
Day change -$0.22 (-6.0%) from $3.67 to $3.45 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in VNDA, bought on each weekday since 2021.
News & filings
What Vanda Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 220 million US dollars in fiscal 2025.
Strengths (1)
- Cash on the balance sheet equals 70% of the company's market value.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Read moreShow less
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
- Sector
- Healthcare
- Shares outstanding
- 59.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $375.8M
- P/B
- 1.1x
- EV / Sales
- 0.6x
- P/S
- 1.7x
- 52-week high
- $9.56
- 52-week low
- $3.45
Profitability
- Operating margin
- -70.0%
- Net margin
- -102.0%
- EBITDA margin
- -64.4%
- ROE
- -67.4%
- ROCE
- -46.2%
- ROIC
- -46.8%
- ROA
- -45.1%
- Asset turnover
- 0.44
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $216.1M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 8.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -5.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1066.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$110.4M
Solvency
- Current ratio
- 2.39
- Debt / Equity
- 0.04
- Debt / Assets
- 0.03
- CFO / Net profit
- 0.50
- Cash / Market cap
- 70.2%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $216.1M |
| Cost of revenue | $13.0M |
| Gross profit | $203.1M |
| Operating expenses | $354.2M |
| Research and development | $109.3M |
| Selling, general and administrative | $237.9M |
| Operating income | -$151.2M |
| Interest and other | $12.5M |
| Pretax income | -$138.7M |
| Tax and other | $81.8M |
| Net income | -$220.5M |
Revenue and net profit
Revenue grew 8.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $254.4M | $6.3M |
| FY2023 | $192.6M | $2.5M |
| FY2024 | $198.8M | -$18.9M |
| FY2025 | $216.1M | -$220.5M |
Cash flows
FY2025: -$109.4M from operations, -$110.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $32.0M | $31.3M |
| FY2023 | $12.8M | $12.4M |
| FY2024 | -$15.8M | -$16.2M |
| FY2025 | -$109.4M | -$110.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $216.1M+8.7%1Y
- EBITDA
- -$139.3M
- Net profit
- -$220.5M
- Cash from operations
- -$109.4M
- Free cash flow
- -$110.4M
- Revenue CAGR, 3Y
- -5.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $216.1M | -$139.3M | -$220.5M | -$110.4M | -67.4% | +8.7% | +1066.5% |
Monthly returns
Month-by-month returns of VNDA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $488.9M |
| Current assets | $347.3M |
| Non-current assets | $141.7M |
| Liabilities | $161.8M |
| Current liabilities | $145.2M |
| Non-current liabilities | $16.6M |
| Equity | $327.2M |
| Paid-in capital | $721.3M |
| Retained earnings | -$394.8M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; VNDA highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc., Perspective Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDAthis company | $375.8M | — | 1.1x | -67.4% | — |
| OmniAb, Inc.OABI | $385.6M | -6.0x | 1.4x | -24.3% | -8.1x |
| Compass Therapeutics, Inc.CMPX | $383.6M | -5.8x | 1.9x | -33.8% | -5.1x |
| Benitec Biopharma Inc.BNTC | $379.6M | -10.0x | 3.9x | -39.0% | -6.8x |
| Viemed Healthcare, Inc.VMD | $377.2M | 25.3x | 2.7x | 10.6% | 7.4x |
| CapsoVision, Inc.CV | $376.7M | -14.9x | 28.4x | -190.9% | -14.7x |
| Lexeo Therapeutics, Inc.LXEO | $375.3M | -3.8x | 1.5x | -40.5% | -3.3x |
| Delcath Systems, Inc.DCTH | $372.5M | 138.0x | 3.3x | 2.4% | 327.0x |
| Perspective Therapeutics, Inc.CATX | $370.7M | -3.6x | 1.8x | -49.8% | -3.4x |
| Peer median | — | -4.8x | 2.3x | -36.4% | -4.2x |
Year-to-date ROI
VNDA since 1 January, against earlier years.
Historical volatility
VNDA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 2.5% |
| FY2023 | -7.2% |
| FY2024 | -20.5% |
| FY2025 | -70.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $216.1M |
| Cost of revenueCost Of Revenue | $13.0M |
| Gross profitGross Profit | $203.1M |
| Operating expensesOperating Expense | $354.2M |
| Research and developmentResearch And Development | $109.3M |
| Selling, general and administrativeSelling General And Administration | $237.9M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $7.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $7.0M |
| Amortization | $7.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $7.0M |
| Total expensesTotal Expenses | $367.3M |
| Operating incomeOperating Income | -$151.2M |
| Interest and other | |
| Pretax incomePretax Income | -$138.7M |
| TaxTax Provision | $81.8M |
| Net incomeNet Income | -$220.5M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $488.9M |
| Current assetsCurrent Assets | $347.3M |
| Non-current assetsTotal Non Current Assets | $141.7M |
| LiabilitiesTotal Liabilities Net Minority Interest | $161.8M |
| Current liabilitiesCurrent Liabilities | $145.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $16.6M |
| EquityTotal Equity Gross Minority Interest | $327.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$109.4M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$109.4M |
| Net income, continuing operationsNet Income From Continuing Operations | -$220.5M |
| Depreciation and amortisationDepreciation And Amortization | $11.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $11.9M |
| Depreciation | $4.9M |
| Amortization cash flowAmortization Cash Flow | $7.0M |
| Amortization of intangiblesAmortization Of Intangibles | $7.0M |
| Amortization of securitiesAmortization Of Securities | -$2.0M |
| Stock-based compensationStock Based Compensation | $9.5M |
| Deferred taxDeferred Tax | $81.4M |
| Deferred income taxDeferred Income Tax | $81.4M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Change in working capitalChange In Working Capital | $8.3M |
| Other non-cash itemsOther Non Cash Items | $1.9M |
| Investing cash flowInvesting Cash Flow | $94.9M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $94.9M |
| Capital expenditureCapital Expenditure | -$1.0M |
| Purchase of PP&EPurchase Of PPE | -$1.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.0M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$112.4M |
| Sale of investmentsSale Of Investment | $208.2M |
| Net investment purchases and salesNet Investment Purchase And Sale | $95.9M |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | -$2.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$2.9M |
| Debt repaidRepayment Of Debt | -$2.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$2.0M |
| Long-term debt repaidLong Term Debt Payments | -$2.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$2.0M |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Other financing chargesNet Other Financing Charges | -$920.0k |
| Change in cashChanges In Cash | -$17.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2.0% |
| Cash at the start of the yearBeginning Cash Position | $102.8M |
| Cash at the end of the yearEnd Cash Position | $85.3M |
| Free cash flowFree Cash Flow | -$110.4M |
Learn while you research
Academy chapters picked for Vanda Pharmaceuticals Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read